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background mortality may be high in these pts, particularly when followed
long-term. Five-year (5 yr) cause of death, determined from autopsy and
death certificate information, was analyzed in 2123 coronary angioplasty pts
(mean age at baseline= 57.5) without acute Ml in the NHLBI PTCA Registry.
There were 200 deaths (9.4%) at 5 yr fu with 52.5% attributed to cardiac
causes. Pts with low ejeetion fraction, prior bypass surgery, inoperable/high
surgical risk, or multi-vessel disease had elevated 5 yr cardiac mortality.
Pts with history of diabetes, congestive heart failure or severe concomitant
disease had elevated rates of both cardiac and non-cardiac mortality. As
length of fu increased, a crossover from cardiac to non-cardiac mortality was
pronounced in older pts (table). In multivariate analysis, age>= 65 strongly
predieted 5 yrrie.kof non-cardiac mortality (RR =3.42, p c 0.001) but was not
predictive of cardiac mortality. Conclusions: Both all-cause and Cardiac-only
mortality should be evaluated in coronary intewention studies involving older
pts and long-term fu. Otherwise, conclusions related to treatment efficacy
and prognostic factors may be inappropriate. Similarly, non-fatal cardiac
outcomes (i.e. anginal atatus, repeat revascularization) seem particularly
important in corona~ Intervention studies involving older pts and long-term
fu.
Patienl age CumulativeCardiac (C)/Non-Cardiac (NC)
at baseline MortalityRats Ratio at Follow-upIntervals
6 men. 1 yr. 2 yr. 3 yr. 4 yr. 5 yr.
<65 vears 5.0 t ,s 2.0 1,7 1,6 1.5
>65 years 1.9 1.4 1,5 1.0 0,s 0.s
Cum. deaths C/NC 26/12 35122 5S/32 68/52 s7i74 lo5te5
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A European survey in nine countries (Czech Republic, Finland, France, Ger-
many, Hungary, Italy, Netherlands, Slovenia and Spain) was undertaken to
measure the potential for secondary prevention of coronary heart disease.
Consecutive patients (S 70 years) from four diagnostic groups – CABG,
PTCA, AMI and acute myocardial ischaemia without infarction-were identi-
fiedfromthecentres and they were then invited forinterviewand examination
at least six montha after the acute procedure or event. 4663 medical records
were reviewed and 3569 (737.) patients atfended for interview. In all patients
combined the prevalence (range between centres) of risk faetor6at interview
was: 19% (13Y0Fin - 32Y0Ne) Currerdcigarette smokers; 25% (19% Net -
33% Fra) had a I.xxly mass index >30 kg/m2; 53% (48% Fra - 61% Cze)
had hypertension; 44% (36% Spa - 56% Ita) had a total cholesterol of ? 5.5
mmol/l; 18% (14% Ger - 27Y0Hun) were diabetic; and 5394 (33% Spa -
71% Fin) had a positive family histoty of CHD. Reported prophylactic drug
therapy was as follows: 87°A (72% Hun – 86% Ita) antiplatelets or anticoag-
ulants; 54% (35% Spa - 76% Fin) beta blockers; 307. (17% Fin - 46% Hun)
ACE inhibitors; 32% (22% Hun - 42% Fra) lipid lowering drugs; and 10%
(7% Fin - 16% Spa) anti-diabetic druge. There was considerable variation
in the prevalence of risk factors and drug use between centres and also
between diagnostic categories. In patients with coronary disease in Europe
there is still considerable medical potential to reduce the risk of a futiher
major ieehaemic event.
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Characteristic N (%) Lipid m~dl
Gsnder: M 5608 (65) Mean Total-C + S.D. 221 l 21
F 997 (15)
Race: White 5s60 (89) Mean HDL+ S.D, 37* 6
Hispanic 4s7 (7)
Black 206 (3) Mean LDL + S.D. 150 i 17
+ Family Hx CHD 1035 (16) Median TG (Range) 15S (35-620)
Active Smoker 816 (12) Ratio
Hypertension 1439 (22) LDUHDL 4.2 * 0.8
Diabetes 153 (2) Totel-C/HDL 6.1 + 1.1
Unique features of this trial are 1) the inclusion of unstable angina in the
primary endpoint, 2) treatment to a LDL goal lees than current NCEP guide-
lines and 3) a cohort that includes women, elderly and those with ‘normal’
cholesterol, mild-moderately elevated LDL and low HDL. The outcome may
help to clarify the role, in primary prevention, of aggressive LDL reduction to
delay or prevent acute coronary events in a relatively high risk population.
m1032 Health Care Delivery: Lessons in
Interventional Cardiology
Tuesday, March 18, 1997, 3:00 p.m.–5:OOp.m.
Anaheim Convention Center, Hall E
Presentation Hour: 4:00 p.m.-5:OOp.m.
11032-38I RegionalVariation ihRatea of Cardiac
Catheterization in Stable Angina Patients
Undergoing Myocardial Perfusion Imaging
L.J, Shaw, R. Hachamovitch, G.V. Heller, T.H. MarWick,K.L. Keeler,
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Substantial variability in the rates of cardiac Catheterization (CATH) have
been reported. In a recent report from Northern New England, noninvasive
stress testing rates were highly correlated with rates of CATH. We compared
rates of CATH s 90 days in 7,706 stable angina patients referred for strees
perfusion imaging (41% reversible defect, CATH rate= 17%). A mt.dtivariable
risk-adjusted logistic regression analyeiewae performed. A clinical risk index
wae derived based upon a patient’s age, eex, eymptoms, and rick faefors
(35% female, mean age =65 years), CATH rates in 4 hoapitals were 29,22,
12, and 12%for Westcoast, Northeast (NE), Central NE, and Midwest. Ueing
Westcoast as a reference, CATH rates were 20-66% lower in other regions
after controlling for clinical and nuclear variables (see fable).
Region n Odda Ratios of Site vs. Westcoast p value
Westcoaat 2,168 -
Northeast 1,416 0.32 (0.26-0,4) 0.002
Central NE 466 0.S (0.67-0.95) <0,001
Midweat 3,656 0.66 (0.51-0.S6) 0.01
Clinical risk (5%), perfusion defect extent (86%), and hospital cite (9%)
contributed independent information in predicting CATH.
Conckraiorr:Considerable regional variability exists in the uee of esrdiac
catheterization instable angina patients that is unexplained by the underlying
clinical or test risk markers. Other factors (e.g. access, referral patterns)
influence catheterization in this population.
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ie a randomized, double-blind placebo-controlled primary preverition trial de-
signed to test the hypothesis that, in addition to a cholesterol lowering diet,
treatment with lovastetin (LOV), toachievea LDLgoalofs llOmg/dl, reduces
the combined incidence of fatal coronary heatt disease (CHD), non-fatal Ml
and uneteble angina.
Over three years, two cites randomized 6605 men and women, with
a mean age of 58 (Range 45-73) to either LOV (20 mg/day) or placebo
(PBO). To reach goal, blinded titration of LOV (and matched PBO) up to 40
mg daily is allowed All participants will be followed until either 320 have
had a primary endpoint or 5 years, whichever occurs last. Independently
adjudicated endpoints will be used for an intention-to-treat analysis. The
baseline characteristics of this study cohort are described below:
Michigan, Ann Arboc Ml, USA
Several risk adjustment models for PTCA mortalily have been recently re-
ported, but external validation. on independent data sets and on high risk
patient populations ie lacking. Between 7/1/94 and 8/1/95, 1476 cxmaeeutive
proeeduree were performed on a high rick patient population characterized
bya high incidence of cardiogenic shock (3.3%) and acute myocardial infarc-
tion (14.3%). in hospital mortality was 3.4% (ehook 48.9%, acute Ml 12.&!’fo,
non Ml 1.4%). Multivariable analysie identified emergency procedure, age,
female gender, eardiogenic shock, pre-procedure administration of iv. NTG,
IABP requirement, LVEDP,and disease eeverity ae independent predietore
of in hospital mortality.Pre-proeedure ueeof aspirin was protective. The area
under the ROC cuwe for mortality wae 0.92, and the Lemeshow-Hosmer
